CD Flashcards
(25 cards)
CD20
B cell marker
CD19
B cell marker
T lymphocyte
CD: 45+ 2+, 3+, 4+, 8+, 5+, 7+
T helper cell
CD: 45+, 3+, 4+
CD: 8-
T Cytotoxic cell
CD: 45+, 3+, 8+
CD: 4-
T reg
CD: 4+, 25+, FOXP3
B lymphocyte
CD: 45+, 19+, 20+, 24+, 38+, 22+
NK cells
CD: 16+, 56+, CD3-, 31, 30, 38
Red blood cells
CD: 235+
Monocytes
CD: CD4, 45+, 14+, 114+, 11a+, 11b+, 16+
Granulocytes
CD: 45+, 11b+, 15+, 24+, 114+, 182+
Myeloid cells
CD: 33+, 13+
Stem cells
CD: 34+, 117+, 31-
Plasma cells
CD: 38+, 138+, 27+, 81+
PNH markers
CD: 55-, 59- on red cells
CD: 24- on grans
CD: 14- on monos
CD55 and 59
complement regulators
deficiency makes them vulnerable to complement mediated
PNH
Acquired somatic PIGA mutation in the bone marrow, impacting the anchor protein for complement mediators CD55 and CD59 on the cells of that population.
Clinical manifestations
*Anaemia
*Transient ischemia -> free Hb binds NO -> vasoconstriction -> GI, cardiovascular, neurological
*Thrombosis -> venous, rarely arterial. CVST, abdominal, hepatic veins. Multifactorial interplay between complement, NO and transient ischaemia. Best prevented by complement inhibitors. Treat symptomatic clots with anticoagulants.
When to test PNH?
Haemolytic anaemia with no apparent cause:
>Haemolytic anaemia
>Normal film
>Negative Coombs
Bone marrow disorders
>AA and MDS
»generally mild PNH
Unexplained thrombosis:
>especially unusual place: CVST, abdominal
or
>occurring despite anticoagulation
PNH diagnosis
loss of associated PIGA ligand antigens in at least 2 haematopoietic cell lines:
>red cells 55 and 59 neg
>FLAER negative
CLL FISH
del13q, del11p, del17p, add12
Hairy cell markers
11c, 103, 123, 25
CLL flow essential markers
19+, 20 dim/+, 5+, 23+/var, kappa, lambda
CLL recommended additional markers
79b-/weak, 81-,10-, fmc7-
43+, ROR1+, 200+,
